New PICCOLO trial analyses showed that mirvetuximab soravtansine achieved 52% response rates and 27-month overall survival in ...

Myriad Genetics’ first quarter results were met with a significant negative market reaction, reflecting investor concerns ...

Moreover, Myriad Genetics was granted two new patents by the U.S. Patent and Trademark Office for bringing its MRD to market, building on three foundational patents awarded last year. The company ...

Myriad Genetics, Inc., a molecular diagnostic testing and precision medicine company, develops and provides molecular tests in the United States and internationally. The company offers molecular ...

MYGN sees growth in oncology and women's health testing, but GeneSight coverage loss clouds the near-term outlook.

The Business Research Company The Business Research Company's At-Home Genetic Testing Market Analysis 2025 – Insights For Long-Term Investm ...

Myriad Genetics Inc MYGN Stock XNAS Rating as of Jul 4, 2025 Download PDF More Actions ...

Myriad Genetics Shares New Clinical Data Demonstrating Sensitivity of Precise MRD Across Multiple Cancer Types Myriad Genetics, Inc. - GlobeNewswire - Mon Jun 2, 8:00AM CDT ...